Drug-Induced Liver Injury
Idiosyncratic Liver Injury Associated with Drugs (ILIAD)
Enrollment Status: OPEN
The goal of the ILIAD protocol is to create a database and bank of biological specimens (DNA, plasma, lymphocytes) from individuals with severe drug-induced liver injury (DILI) due to isoniazid (INH), phenytoin (Dilantin), amoxicillin/clavulanate (Augmentin), or valproic acid (Depakote) after January 1, 1994. This study is funded by the NIH/NIDDK.
Study Design
- Telephone or personal interview of medical history surrounding DILI event
- Single blood draw
- Participant receives $75
A Multicenter, Longitudinal Study of Drug-Induced and Complementary and Alternative Medication-Induced Liver Injury
Enrollment Status: OPEN
The goal of this NIH study is to prospectively identify bona fide cases of liver injury due to drugs and complementary and alternative medications (CAM) within 6 months of onset. Clinical data, blood, DNA, and urine will be collected from affected patients and matched controls for mechanistic and genetic studies.
Study Design
- All subjects have a baseline and 6-month follow-up visit at the General Clinical Research Center, which includes surveys, medical history, blood and urine collection.
- Patients with liver injury at 6 months return for 12- and 24-month visits.
Costs
- Costs of study lab tests provided by sponsor (NIDDK).
- Subjects receive $50 for each completed study visit.
Contact persons:
- Suzanne Welch at (734) 936-4886 or toll free 1-866-UM-LIVER or e-mail swelc@umich.edu)
- Robert Fontana, MD e-mail: rfontana@umich.edu
For more information, see the following web sites:
Drug-Induced Liver Injury Network
NIH funds network to study drug-induced liver injury
Press Release: U-M helps lead national study of liver damage
